Additional file 1: of Identification of a large intronic transposal insertion in SLC17A5 causing sialic acid storage disease

Predicted sequences resulting from the LINE-1 retrotransposon insertion. (PDF 162 kb

HIV viral loads at baseline and day 84 of treatment and AUC of study participants who failed to attain viral suppression to below detection by day 84.

<p>Data are arranged in order of increasing AUC.</p

Final model pharmacokinetic parameters.

<p>Ka = Mean population absorption rate constant, V = Mean population Volume of distribution, CL = Mean population clearance, F1 = Bioavailability fraction, IIV CL = inter-individual variability on Clearance in the population, RV = residual variability.</p

The individually weighted residuals (WRES) are plotted <i>vs.</i> time.

<p>The dashed line is the zero reference line while the solid line is a smooth nonparametric regression line. The plot demonstrates a good fit of all time point concentration data by the model.</p

Distribution of estimated patient AUC values by CYP2B6 genotype.

<p>CYP2B6*1/*1, CYP2B6 *1/*6, and CYP2B6 *6/*6. Dotted line = the mean AUC value in the product label.</p

Simulation based AUC for 300

a<p>The frequency of each group in these simulations reflects the proportional frequency of the groups in the observed patient dataset.</p

Area under the curve (AUC) NONMEM estimate values for ABCB1 c. 4046A>G and or CYP2B6* 6 genotypes.

<p>The estimations are based on the predicted individual apparent clearance and bioavailability values.</p><p>mut = heterozygous plus homozygous variant, wt = homozygous variants.</p><p>Four patients did not have a reported ABCB1 genotype and one patient was ABCB1 G/G. These five subjects are not included in these summary statistics for ABCB1, but are included in the general CYP2B6*6 summary above.</p

Additional file 1: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

A comprehensive summary of sample sizes and cohorts in pharmacogenetics studies in the field of multiple sclerosis. (DOCX 23 kb

Additional file 12: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Details on participating institutional or clinical sites at which Institutional Review Boards or Ethics Committees approved the clinical trials included in the study. (DOCX 59 kb